PT1007093E - Metodos para o tratamento de desordens atraves da utilizacao de interleucina-9 e seus antagonistas - Google Patents

Metodos para o tratamento de desordens atraves da utilizacao de interleucina-9 e seus antagonistas

Info

Publication number
PT1007093E
PT1007093E PT97939680T PT97939680T PT1007093E PT 1007093 E PT1007093 E PT 1007093E PT 97939680 T PT97939680 T PT 97939680T PT 97939680 T PT97939680 T PT 97939680T PT 1007093 E PT1007093 E PT 1007093E
Authority
PT
Portugal
Prior art keywords
treatment
interleucin
antagonists
disorders
methods
Prior art date
Application number
PT97939680T
Other languages
English (en)
Inventor
Jean-Christophe Renauld
Mary-Christine Many
Francois Huaux
Dominique Lison
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Publication of PT1007093E publication Critical patent/PT1007093E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/206—IL-9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT97939680T 1996-08-30 1997-08-29 Metodos para o tratamento de desordens atraves da utilizacao de interleucina-9 e seus antagonistas PT1007093E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/706,302 US5830454A (en) 1996-08-30 1996-08-30 Method for treating cell mediated autoimmune disorders using interleukin-9

Publications (1)

Publication Number Publication Date
PT1007093E true PT1007093E (pt) 2004-03-31

Family

ID=24837006

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97939680T PT1007093E (pt) 1996-08-30 1997-08-29 Metodos para o tratamento de desordens atraves da utilizacao de interleucina-9 e seus antagonistas

Country Status (11)

Country Link
US (2) US5830454A (pt)
EP (1) EP1007093B1 (pt)
JP (1) JP2000517322A (pt)
AT (1) ATE252911T1 (pt)
AU (1) AU721908B2 (pt)
CA (1) CA2263935A1 (pt)
DE (1) DE69725897T2 (pt)
DK (1) DK1007093T3 (pt)
ES (1) ES2210569T3 (pt)
PT (1) PT1007093E (pt)
WO (1) WO1998008545A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040049014A1 (en) * 1988-12-28 2004-03-11 Protein Design Labs, Inc. Humanized immunoglobulins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5830454A (en) * 1996-08-30 1998-11-03 Ludwig Institute For Cancer Research Method for treating cell mediated autoimmune disorders using interleukin-9
WO1998027997A1 (en) * 1996-12-20 1998-07-02 Magainin Pharmaceuticals Inc. A method for diagnosis and treatment of inflammatory bowel diseases including crohn's disease and chronic ulcerative colitis
US6328955B1 (en) * 2000-01-25 2001-12-11 Ludwig Institute For Cancer Research Method for regulating IL-10 with IL-9, and applications thereof
US6586336B2 (en) 2001-08-31 2003-07-01 Oriol, Inc. Chemical-mechanical-polishing station
JP2005535572A (ja) * 2002-04-12 2005-11-24 メディミューン，インコーポレーテッド 組換え抗インターロイキン−９抗体
GB0526000D0 (en) * 2005-12-21 2006-02-01 Ares Trading Sa Cytokine receptor
WO2012129394A2 (en) 2011-03-22 2012-09-27 Brigham And Women's Hospital, Inc. Methods and compositions for the treatment of cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587302A (en) * 1988-09-19 1996-12-24 Ludwig Institute For Cancer Research T cell growth factor
US5414071A (en) * 1989-05-23 1995-05-09 Genetics Institute, Inc. Human cytokine IL-9
US5580753A (en) * 1989-05-23 1996-12-03 Ludwig Institute For Cancer Research DNA encoding the human cytokine, interleukin-9
IE910916A1 (en) * 1990-03-23 1991-09-25 Ludwig Inst For Cancer Res Gsf Method for enhanced growth and proliferation of mast cells
US5246701A (en) * 1990-10-05 1993-09-21 Ludwig Institute For Cancer Research Method for inhibiting production of IgE by using IL-9 inhibitors
US5132109A (en) * 1990-10-05 1992-07-21 Ludwig Institute For Cancer Research Method for inhibiting production of ige and method for enhancing production of igg using interleukin 9 and inhibitors thereof
DE69635305T2 (de) * 1995-08-24 2006-07-06 Genaera Corp. Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
US5830454A (en) * 1996-08-30 1998-11-03 Ludwig Institute For Cancer Research Method for treating cell mediated autoimmune disorders using interleukin-9

Also Published As

Publication number Publication date
EP1007093B1 (en) 2003-10-29
WO1998008545A1 (en) 1998-03-05
US5935929A (en) 1999-08-10
AU4171297A (en) 1998-03-19
JP2000517322A (ja) 2000-12-26
ES2210569T3 (es) 2004-07-01
DE69725897D1 (de) 2003-12-04
EP1007093A1 (en) 2000-06-14
ATE252911T1 (de) 2003-11-15
EP1007093A4 (en) 2000-11-08
AU721908B2 (en) 2000-07-20
CA2263935A1 (en) 1998-03-05
US5830454A (en) 1998-11-03
DE69725897T2 (de) 2004-08-26
DK1007093T3 (da) 2004-01-26

Similar Documents

Publication Publication Date Title
ATE250412T1 (de) Muskarinische antagonisten zur behandlung von presbyopie
ES2164916T3 (es) Tratamiento de la esclerosis multiple.
PT867184E (pt) Utilizacao de tiagabina para o tratamento de desordens do sono
FI971116A0 (fi) Fotodynaaminen terapia selektiivisessä solujen inaktivoinnissa veressä sekä immuunijärjestelmän häiriötautien hoito
EP0954303A4 (en) METHODS FOR TREATING MENTAL ILLNESSES, INFLAMMATION AND PAIN
DE69822295D1 (de) Verwendung von misoprostol und/oder misoprostolsäure zur behandlung von erektionsstörungen
PT1007093E (pt) Metodos para o tratamento de desordens atraves da utilizacao de interleucina-9 e seus antagonistas
DE69711078D1 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
IS4628A (is) Frumuröð sem myndar kvalastillandi efni til nota í meðferð gegn sársauka
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
NO20002649D0 (no) Anvendelse av en blanding av diol og en alfa-hydroksysyre for behandling av hyperkeratotiske hudsykdommer
ID23175A (id) Penggunaan benzopiranol untuk mengobati gangguan syaraf
PT862454E (pt) Novas utilizacoes de ctla-8 de mamifero e reagentes relacionados
IL129460A0 (en) Use of lofexidine in the treatment of behavioral disorders
ATE369143T1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
EP0904094A4 (en) TREATMENT OF BONE DISEASES USING ADRENOMEDULLINE
EP0745597A3 (en) Novel melatonergic indanyl piperazines or homopiperazines
ATE216884T1 (de) Verwendung von sulbutiamin zur behandlung von psychomotorischen oder psychointellektuellen beschwerden
ITRM930034A0 (it) Agente attivo per ridurre il livello ematico di glucocorticoidi e prevenire disturbi cerebrali da stress e senilita'.
BR9912117A (pt) Uso de estimulador de captação de glicose para reduzir a apoptose
葛通远 et al. AN APPROACH TO THE MECHANISMS OF LASER ACUPUNCTURE IN TREATMENT OF EXOPHTHALMIC HYPERTHYROIDISM
RU93057223A (ru) Способ лечения параличей и парезов
丁罗兰 et al. THE DAMAGE OF THE NEUROLOGICAL SYSTEM OF THE ENDEMIC FLUOROSIS, THE CLINICAL ANALYSIS OF 33 CASES
RU95116393A (ru) Способ лечения заболеваний спинного мозга
FloraIPPOLITI PRELIMINARY RESEARCH ON ACUPUNCTURE EFFECTS IN IMMUNOLOGY